Premium
The top 10 research priorities for psoriasis in the U.K.: results of a James Lind Alliance psoriasis Priority Setting Partnership
Author(s) -
MajeedAriss R.,
McPhee M.,
McAteer H.,
Griffiths C.E.M.,
Young H.
Publication year - 2019
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.18209
Subject(s) - psoriasis , alliance , general partnership , dermatology , medicine , plaque psoriasis , family medicine , political science , law
Psoriasis is an immune-mediated inflammatory skin disease, with a prevalence of 0·09% to 11·4%, which affects approximately two million people in the U.K.1,2 It has a significant psychological and social impact on affected individuals, is associated with co-morbidities such as depression, cardiovascular disease and inflammatory arthritis, and confers a substantial economic burden on the National Health Service.1-3 Access to appropriate care that addresses the high health-care burden and complex interlinked physical, psychological and social needs of those who have psoriasis is often poor. This article is protected by copyright. All rights reserved.